Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Validation of the International Prognostic Score for Thrombosis in Essential Thrombocythemia (IPSET) in Patients with Pre-Fibrotic Primary Myelofibrosis

Paola Guglielmelli, MD PhD, Alessandra Carobbio, BSc, Elisa Rumi, MD, Valerio De Stefano, MD, Lara Mannelli, MD, Francesco Mannelli, MD, Giada Rotunno, PhD, Giacomo Coltro, MD, Silvia Betti, MD PhD, Chiara Cavalloni, MD, Maria Chiara Finazzi, MD, Juergen Thiele, MD PhD, Mario Cazzola, MD, Alessandro M. Vannucchi, MD, Tiziano Barbui, MD

Blood (2019) 134 (Supplement_1): 1657.

https://doi.org/10.1182/blood-2019-124302

Published: 2019

Journal Articles

Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, Philomena Colucci, DO, MS, Dilan Paranagama, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 2948.

https://doi.org/10.1182/blood-2019-124343

Published: 2019

Journal Articles

Heterogeneity of Bone Marrow Morphology in Patients with Polycythemia Vera Resistant to First and Second Line Therapies - Impact of Hydroxyurea Dosage on MDS-like Progression

Hans Michael Kvasnicka, Gina Liviana Frank, Marlene Lemp, Fabian Lang, MD, Juergen Thiele, MD

Blood (2017) 130 (Supplement 1): 2913.

https://doi.org/10.1182/blood.V130.Suppl_1.2913.2913

Published: 2017

Journal Articles

Impact of High Molecular Risk Mutations on Overall Survival in WHO-Defined Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis

Heinz Gisslinger, Martin Schalling, Bettina Gisslinger, Roland Jäger, PhD, Edith Bogner, Ashot S Harutyunyan, PhD, Jelena D Milosevic Feenstra, Nicole C.C. Them, Maria-Theresa Krauth, MD, Leonhard Muellauer, MD, Juergen Thiele, MD PhD, Robert Kralovics

Blood (2016) 128 (22): 1931.

https://doi.org/10.1182/blood.V128.22.1931.1931

Published: 2016

Journal Articles

Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, William Sun, PhD, Ahmad Naim, MD, Smitha Svaraman, PhD, Jessy Gao, MA, Jason R. Gotlib, MD, Vikas Gupta, MD FRCP, FRCPath, Kim-Hien Dao, DO, PhD, Moshe Talpaz, MD, Elliott F. Winton, MD, Jimmie H. Harvey, Jr., MD, Srdan Verstovsek, MD PhD

Blood (2016) 128 (22): 1949.

https://doi.org/10.1182/blood.V128.22.1949.1949

Published: 2016

Journal Articles

Clinical Impact of Bone Marrow Morphology for the Diagnosis of Essential Thrombocythemia: Comparison Between the British Standards (BCSH) and the WHO Criteria

Georg Jeryczynski, MD, Juergen Thiele, MD, Bettina Gisslinger, Maria Theresa Krauth, MD, Martin Schalling, MSc, Ana-Iris Schiefer, MD, Ingrid Simonitsch-Klupp, MD, Leonhard Muellauer, MD, Heinz Gisslinger, MD

Blood (2015) 126 (23): 2816.

https://doi.org/10.1182/blood.V126.23.2816.2816

Published: 2015

Journal Articles

Practice-Relevant Revision of Ipset-Thrombosis Based on 1019 Patients with WHO-Defined Essential Thrombocythemia

Tiziano Barbui, MD, Alessandro M. Vannucchi, Veronika Buxhofer-Ausch, Valerio De Stefano, MD, Silvia Betti, MD, Alessandro Rambaldi, Elisa Rumi, MD, Marco Ruggeri, MD, Francesco Rodighiero, Maria Luigia Randi, Irene Bertozzi, Heinz Gisslinger, MD, Guido Finazzi, MD, Alessandra Carobbio, Juergen Thiele, MD, Francesco Passamonti, MD, Chiara Falcone, Ayalew Tefferi, MD

Blood (2015) 126 (23): 4055.

https://doi.org/10.1182/blood.V126.23.4055.4055

Published: 2015

Journal Articles

Calreticulin Mutation Status Predicts Improved Disease Outcome in Prefibrotic Primary Myelofibrosis but Not in WHO-Defined Essential Thrombocythemia

Heinz Gisslinger, MD, Juergen Thiele, MD PhD, Bettina Gisslinger, MSc, Tiina Berg, B.Sc., Martin Schalling, M.Sc., Ashot S Harutyunyan, MD, Jelena D. Milosevic, M.Sc., Klaudia Bagienski, M.Sc., Nicole C.C. Them, M.Sc., Veronika Buxhofer-Ausch, Guenther Nirnberger, Leonhard Muellauer, MD, Robert Kralovics, PhD

Blood (2014) 124 (21): 3167.

https://doi.org/10.1182/blood.V124.21.3167.3167

Published: 2014

Journal Articles

Ruxolitinib-Induced Modulation of Bone Marrow Microenvironment in Patients with Myelofibrosis Is Associated with Inflammatory Cytokine Levels

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, William Sun, PhD, Jorge E. Cortes, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 3182.

https://doi.org/10.1182/blood.V124.21.3182.3182

Published: 2014

Journal Articles

Changes in Activated Bone Marrow Macrophages and Mast Cells in Patients with Myelofibrosis Following Ruxolitinib Therapy

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MDPhD, Carlos E. Bueso-Ramos, MD PhD, Shilpa Kamalanabhaiah, Jorge E. Cortes, MD, Hagop Kantarjian, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 3184.

https://doi.org/10.1182/blood.V124.21.3184.3184

Published: 2014

Journal Articles

Ruxolitinib Therapy Effectively Modulates CD34 + Hematopoietic Progenitors and Bone Marrow Angiogenesis in Patients with Myelofibrosis

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MDPhD, Carlos E. Bueso-Ramos, MD PhD, Shilpa Kamalanabhaiah, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 4578.

https://doi.org/10.1182/blood.V124.21.4578.4578

Published: 2014

Journal Articles

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

Ayalew Tefferi, Paola Guglielmelli, Dirk R. Larson, Christy Finke, Emnet A. Wassie, Lisa Pieri, Naseema Gangat, Rajmonda Fjerza, Alem A. Belachew, Terra L. Lasho, Rhett P. Ketterling, Curtis A. Hanson, Alessandro Rambaldi, Guido Finazzi, Juergen Thiele, Tiziano Barbui, Animesh Pardanani, Alessandro M. Vannucchi

Blood (2014) 124 (16): 2507–2513.

https://doi.org/10.1182/blood-2014-05-579136

Published: 2014

Includes: Supplemental data

Journal Articles

The Kinetic Of Bone Marrow Fibrosis Regression Predicts Outcome In Myelofibrosis Patients After Allogeneic SCT

Nicolaus Kröger, MD, Haefaa Alchalby, MD, Tatjana Zabelina, MD, Hans-Michael Kvasnicka, MD, Juergen Thiele, MD, PhD, Guntram Büsche, MD, Hans Kreipe, MD

Blood (2013) 122 (21): 2078.

https://doi.org/10.1182/blood.V122.21.2078.2078

Published: 2013

Journal Articles

Effects Of Ruxolitinib Therapy On Megakaryocyte Morphology and Inflammatory Bone Marrow Reaction In Patients With Myelofibrosis

Hans Michael Kvasnicka, MD, PhD, Juergen Thiele, MD, PhD, Carlos E. Bueso-Ramos, MD, PhD, Shilpa Kamalanabhaiah, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD, PhD

Blood (2013) 122 (21): 4056.

https://doi.org/10.1182/blood.V122.21.4056.4056

Published: 2013

Journal Articles

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

Ayalew Tefferi, Francisco Cervantes, Ruben Mesa, Francesco Passamonti, Srdan Verstovsek, Alessandro M. Vannucchi, Jason Gotlib, Brigitte Dupriez, Animesh Pardanani, Claire Harrison, Ronald Hoffman, Heinz Gisslinger, Nicolaus Kröger, Juergen Thiele, Tiziano Barbui, Giovanni Barosi

Blood (2013) 122 (8): 1395–1398.

https://doi.org/10.1182/blood-2013-03-488098

Published: 2013

Includes: Supplemental data

Journal Articles

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial

Heinz Gisslinger, Mirjana Gotic, Jerzy Holowiecki, Miroslav Penka, Juergen Thiele, Hans-Michael Kvasnicka, Robert Kralovics, Petro E. Petrides

Blood (2013) 121 (10): 1720–1728.

https://doi.org/10.1182/blood-2012-07-443770

Published: 2013

Includes: Supplemental data

Journal Articles

Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)

Tiziano Barbui, Guido Finazzi, Alessandra Carobbio, Juergen Thiele, Francesco Passamonti, Elisa Rumi, Marco Ruggeri, Francesco Rodeghiero, Maria Luigia Randi, Irene Bertozzi, Heinz Gisslinger, Veronika Buxhofer-Ausch, Valerio De Stefano, Silvia Betti, Alessandro Rambaldi, Alessandro M. Vannucchi, Ayalew Tefferi

Blood (2012) 120 (26): 5128–5133.

https://doi.org/10.1182/blood-2012-07-444067

Published: 2012

Journal Articles

Decanucleotide Insertion Polymorphism of F7 Influences Significantly the Risk of Thrombosis in Patients with Essential Thrombocythemia

Veronika Buxhofer-Ausch, Damla Olcaydu, Bettina Gisslinger, Martin Schalling, Sophie Frantal, Juergen Thiele, Leonhard Müllauer, Hans-Michael Kvasnicka, Robert Kralovics, Heinz Gisslinger

Blood (2012) 120 (21): 1730.

https://doi.org/10.1182/blood.V120.21.1730.1730

Published: 2012

Journal Articles

Risk Factors for Thrombosis Among 1,545 Patients with Polycythemia Vera: An International Study.

Guido Finazzi, MD, Elisa Rumi, MD, Alessandro M. Vannucchi, MD, Maria Luigia Randi, Ilaria Nichele, Heinz Gisslinger, MD, Rakhee Vaidya, MD, Mario Cazzola, Alessandro Rambaldi, MD, Lisa Pieri, MD, Francesco Rodeghiero, MD, Animesh Pardanani, MBBS, PhD, Juergen Thiele, Francesco Passamonti, MD, T Barbui, Ayalew Tefferi, MD

Blood (2012) 120 (21): 2849.

https://doi.org/10.1182/blood.V120.21.2849.2849

Published: 2012

Journal Articles

A PROGNOSTIC MODEL to PREDICT SURVIVAL In WHO-DEFINED ESSENTIAL THROMBOCYTHEMIA: A STUDY by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

Blood (2011) 118 (21): 1746.

https://doi.org/10.1182/blood.V118.21.1746.1746

Published: 2011

NARROW

Validation of the International Prognostic Score for Thrombosis in Essential Thrombocythemia (IPSET) in Patients with Pre-Fibrotic Primary Myelofibrosis

Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study

Heterogeneity of Bone Marrow Morphology in Patients with Polycythemia Vera Resistant to First and Second Line Therapies - Impact of Hydroxyurea Dosage on MDS-like Progression

Impact of High Molecular Risk Mutations on Overall Survival in WHO-Defined Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis

Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study

Clinical Impact of Bone Marrow Morphology for the Diagnosis of Essential Thrombocythemia: Comparison Between the British Standards (BCSH) and the WHO Criteria

Practice-Relevant Revision of Ipset-Thrombosis Based on 1019 Patients with WHO-Defined Essential Thrombocythemia

Calreticulin Mutation Status Predicts Improved Disease Outcome in Prefibrotic Primary Myelofibrosis but Not in WHO-Defined Essential Thrombocythemia

Ruxolitinib-Induced Modulation of Bone Marrow Microenvironment in Patients with Myelofibrosis Is Associated with Inflammatory Cytokine Levels

Changes in Activated Bone Marrow Macrophages and Mast Cells in Patients with Myelofibrosis Following Ruxolitinib Therapy

Ruxolitinib Therapy Effectively Modulates CD34 + Hematopoietic Progenitors and Bone Marrow Angiogenesis in Patients with Myelofibrosis

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

The Kinetic Of Bone Marrow Fibrosis Regression Predicts Outcome In Myelofibrosis Patients After Allogeneic SCT

Effects Of Ruxolitinib Therapy On Megakaryocyte Morphology and Inflammatory Bone Marrow Reaction In Patients With Myelofibrosis

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial

Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)

Decanucleotide Insertion Polymorphism of F7 Influences Significantly the Risk of Thrombosis in Patients with Essential Thrombocythemia

Risk Factors for Thrombosis Among 1,545 Patients with Polycythemia Vera: An International Study.

A PROGNOSTIC MODEL to PREDICT SURVIVAL In WHO-DEFINED ESSENTIAL THROMBOCYTHEMIA: A STUDY by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only